Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate

Rheumatology

Volumn 49, Issue 11, 2010, Pages 2024-2036

  Dooley, Audrey ^a   Shi Wen, Xu ^a   Aden, Nima ^a   Tranah, Thomas ^a   Desai, Nirupa ^a   Denton, Christopher P ^a   Abraham, David J ^a   Bruckdorfer, Richard ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antioxidant; Collagen type I; Epigallocatechin 3 gallate; Extracellular matrix proteins; Fibroblast; Fibronectin; Reactive oxygen species; Scleroderma; Systemic sclerosis

Indexed keywords

ACETYLCYSTEINE; ALPHA SMOOTH MUSCLE ACTIN; CATALASE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DICHLOROFLUORESCEIN; DIPHENYLIODONIUM SALT; EPIGALLOCATECHIN GALLATE; FIBRONECTIN; I KAPPA B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR BB; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL LINE; CELL LYSATE; CONTROLLED STUDY; CULTURE MEDIUM; DNA BINDING; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RHEUMATOLOGY; SKIN FUNCTION; SMOOTH MUSCLE; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANTIOXIDANTS; BIOPSY; CASE-CONTROL STUDIES; CATECHIN; CELLS, CULTURED; COLLAGEN TYPE I; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; FIBRONECTINS; HUMANS; REACTIVE OXYGEN SPECIES; SCLERODERMA, SYSTEMIC;

EID: 78649373143     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq208     Document Type: Article

References (50)

1. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:134-44.
2. Chen Y, Shi-Wen X, van BJ et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005;167:1699-711.
3. Chen Y, Shi-Wen X, Eastwood M et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006;54: 1309-16.
4. Fonseca C, Lindahl GE, Ponticos M et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007;357:1210-20.
5. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807-16.
6. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007;9:136-43.
7. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
8. Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin Immunopathol 2008;30:329-37.
9. Svegliati S, Cancello R, Sambo P et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005;280:36474-82.
10. Hecker L, Vittal R, Jones T et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-81.
11. Cucoranu I, Clempus R, Dikalova A et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005;97:900-7.
12. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 1999;189: 273-8.
13. Dooley A, Gao B, Bradley N et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology 2006;45:676-84.
14. Sambo P, Baroni SS, Luchetti M et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001;44: 2653-64.
15. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995;38:1060-7.
16. Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39: 1146-50.
17. Dooley A, Low SY, Holmes A et al. Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosis. Rheumatology 2008;47:272-80.
18. Dooley A, Gao B, Shi-Wen X et al. Effect of nitric oxide and peroxynitrite on type I collagen synthesis in normal and scleroderma dermal fibroblasts. Free Radic Biol Med 2007;43:253-64.
19. Herrick AL, Matucci CM. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001;19:4-8.
20. Denton CP, Bunce TD, Darado MB et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology 1999;38:309-15.
21. Cracowski JL, Girolet S, Imbert B et al. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic Biol Med 2005;38:98-103.
22. Mavrikakis ME, Lekakis JP, Papamichael CM, Stamatelopoulos KS, Kostopoulos C, Stamatelopoulos SF. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis. Int J Vitam Nutr Res 2003;73:3-7.
23. Salsano F, Letizia C, Proietti M et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon. Int J Immunopathol Pharmacol 2005;18:761-70.
24. Sambo P, Amico D, Giacomelli R et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001;28:2257-62.
25. Bruckdorfer KR. Antioxidants and CVD. Proc Nutr Soc 2008;67:214-22.
26. Tipoe GL, Leung TM, Hung MW, Fung ML. Green tea polyphenols as an anti-oxidant and anti-inflammatory agent for cardiovascular protection. Cardiovasc Hematol Disord Drug Targets 2007;7:135-44.
27. Sabetkar M, Low SY, Bradley NJ, Jacobs M, Naseem KM, Richard BK. The nitration of platelet vasodilator stimulated phosphoprotein following exposure to low concentrations of hydrogen peroxide. Platelets 2008;19:282-92.
28. Chen A, Zhang L, Xu J, Tang J. The antioxidant (-)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression. Biochem J 2002;368:695-704.
29. Chen A, Zhang L. The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor. J Biol Chem 2003;278:23381-9.
30. Nakamuta M, Higashi N, Kohjima M et al. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int J Mol Med 2005;16:677-81.
31. Asaumi H, Watanabe S, Taguchi M et al. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits ethanol-induced activation of pancreatic stellate cells. Eur J Clin Invest 2006;36:113-22.
32. Meng M, Li YQ, Yan MX, Kou Y, Ren HB. Effects of epigallocatechin gallate on diethyldithiocarbamateinduced pancreatic fibrosis in rats. Biol Pharm Bull 2007; 30:1091-6.
33. Ahn HY, Hadizadeh KR, Seul C, Yun YP, Vetter H, Sachinidis A. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol Biol Cell 1999;10:1093-104.
34. Park G, Yoon BS, Moon JH et al. Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. J Invest Dermatol 2008;128:2429-41.
35. Khan N, Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett 2008;269:269-80.
36. Stangl V, Dreger H, Stangl K, Lorenz M. Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res 2007;73:348-58.
37. Yang CS, Lambert JD, Hou Z, Ju J, Lu G, Hao X. Molecular targets for the cancer preventive activity of tea polyphenols. Mol Carcinog 2006;45:431-5.
38. Rice-Evans C. Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Proc Soc Exp Biol Med 1999;220: 262-6.
39. Suzukawa K, Miura K, Mitsushita J et al. Nerve growth factor-induced neuronal differentiation requires generation of Rac1-regulated reactive oxygen species. J Biol Chem 2000;275:13175-8.
40. Akhmetshina A, Dees C, Pileckyte M et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008;58:2553-64.
41. Suzuki Y, Hattori S, Isemura M. Epigallocatechin-3-O-gallate inhibits fibroblast contraction of floating collagen gel: interaction between epigallocatechin-3-O-gallate and platelet derived growth factor. Biosci Biotechnol Biochem 2004;68:1817-20.
42. Li HL, Huang Y, Zhang CN et al. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med 2006;40:1756-75.
43. Nishikawa H, Wakano K, Kitani S. Inhibition of NADPH oxidase subunits translocation by tea catechin EGCG in mast cell. Biochem Biophys Res Commun 2007;362: 504-9.
44. Yasuda Y, Shimizu M, Sakai H et al. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R. Chem Biol Interact 2009;182:159-64.
45. Sakata R, Ueno T, Nakamura T, Sakamoto M, Torimura T, Sata M. Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol 2004;40:52-9.
46. Ehrlich HP, Rockwell WB, Cornwell TL, Rajaratnam JB. Demonstration of a direct role for myosin light chain kinase in fibroblast-populated collagen lattice contraction. J Cell Physiol 1991;146:1-7.
47. Hinz B, Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol 2003;14:538-46.
48. Chow HH, Hakim IA, Vining DR et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin Cancer Res 2005;11:4627-33.
49. Katiyar S, Elmets CA, Katiyar SK. Green tea and skin cancer: photoimmunology, angiogenesis and DNA repair. J Nutr Biochem 2007;18:287-96.
50. Katiyar SK, Afaq F, Perez A, Mukhtar H. Green tea polyphenol (-)-epigallocatechin-3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress. Carcinogenesis 2001;22:287-94.